HER2阳性乳腺癌:MRI及临床病理特征与肿瘤浸润淋巴细胞的相关性
该回顾性研究纳入212例HER2阳性乳腺癌女性,按肿瘤浸润淋巴细胞(TIL)水平分为低TIL(<10%)和高TIL(≥10%)组,探讨临床病理及MRI特征与TIL水平的关联。多因素分析显示,组织学分级3级、高肿瘤细胞密度、较低的导管原位癌伴随频率以及T2WI瘤周水肿与高TIL水平相关;亚组分析中,HR阴性/HER2阳性组高肿瘤细胞密度、瘤周水肿和低ADC值为独立预测因子。结论提示MRI瘤周水肿有助于预测HER2阳性乳腺癌的高TIL水平。
要点
- T2WI瘤周水肿与HER2阳性乳腺癌高TIL水平相关(OR=2.83)。
- 组织学分级3级、高肿瘤细胞密度与高TIL水平相关。
- HR阴性/HER2阳性亚组中,低ADC值为高TIL的独立预测因子(OR=11.69)。
关键影像表现/征象
- 高TIL组T2WI瘤周水肿频率为71.1%,低TIL组为50.4%。
- 高TIL组组织学分级3级频率为78.4%,低TIL组为52.2%。
- 高TIL组中位肿瘤细胞密度为60%,低TIL组为50%。
- 高TIL组伴随导管原位癌频率为86.6%,低TIL组为94.8%。
诊断标准与关键数值
- TIL水平以10%为界分为低TIL(<10%)和高TIL(≥10%)组,低TIL组115例(54.2%),高TIL组97例(45.8%)。
- 多因素分析显示高TIL与组织学分级3级(OR=3.98)、高肿瘤细胞密度(OR=4.59)、较低的伴随导管原位癌频率(OR=0.16)及T2WI瘤周水肿(OR=2.83)相关(均p<.05)。
- HR阳性/HER2阳性亚组中,组织学分级3级为高TIL的独立预测因子(OR=5.03,p=.002)。
- HR阴性/HER2阳性亚组中,高肿瘤细胞密度(OR=9.06,p=.002)、瘤周水肿(OR=5.23,p=.03)和低ADC值(OR=11.69,p=.047)为高TIL的独立预测因子。
- 三名放射科医生对瘤周水肿的读者间一致性为中等(κ=0.432-0.539)。
临床应用与阅片要点
- 治疗前MRI若见T2WI瘤周水肿,可提示高TIL水平可能,辅助评估免疫活性相关临床结局。
- 结合组织学分级、肿瘤细胞密度及HR状态综合判断TIL水平,尤其HR阴性/HER2阳性患者需关注ADC值。
- 瘤周水肿的读者间一致性中等,阅片时需注意判读标准以减少差异。
局限性
- 单中心回顾性研究,可能存在选择偏倚。
- 仅采用第一阅片者结果进行后续分析,未充分利用三读者数据。
- 样本仅限HER2阳性乳腺癌,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Tumor-infiltrating lymphocytes (TILs) are associated with therapeutic outcomes and prognosis in patients with human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. Identification of TIL levels is clinically relevant. OBJECTIVE. The purpose of our study was to explore associations of clinicopathologic and MRI features with TIL levels in patients with HER2-positive breast cancer. METHODS. A total of 212 consecutive women (mean age, 54.0 years) diagnosed with HER2-positive breast cancer between January 2017 and December 2019 were included in this retrospective study. Patients were divided into low-TIL (< 10%) and high-TIL (≥ 10%) groups. Three breast radiologists independently reviewed images; interreader agreement was assessed, and the first reader's findings were used for further analysis. Associations of clinicopathologic and MRI features with TIL levels were evaluated using multivariable logistic regression analysis. Subanalysis of TIL levels by hormone receptor (HR) status was also performed. RESULTS. A total of 115 (54.2%) patients had low TIL levels, and 97 (45.8%) patients had high TIL levels. A high TIL level was associated (all, p < .05) with histologic grade 3 (odds ratio [OR] = 3.98; frequency, 78.4% vs 52.2% in high- vs low-TIL groups, respectively), high tumor cellularity (OR = 4.59; median cellularity, 60% vs 50%), lower frequency of associated ductal carcinoma in situ (OR = 0.16; frequency, 86.6% vs 94.8%), and higher frequency of peritumoral edema on T2-weighted images (OR = 2.83; 71.1% vs 50.4%). In subgroup analysis by HR status, histologic grade 3 (OR = 5.03, p = .002) was a significant independent predictor of high TIL level in the HR-positive/HER2-positive group, whereas high tumor cellularity (OR = 9.06, p = .002), peritumoral edema (OR = 5.23, p = .03), and low ADC (OR = 11.69, p = .047) were independent predictors of high TIL level in the HR-negative/HER2-positive group. Interreader agreement for peritumoral edema was moderate among the three radiologists (к = 0.432-0.539). CONCLUSION. Peritumoral edema on MRI and the histopathologic feature of tumor aggressiveness help predict high TIL levels in patients with HER2-positive breast cancer. CLINICAL IMPACT. Pretreatment MRI features may serve as a useful tool for assessing TIL levels in patients with HER2-positive breast cancer and for helping to classify patients with variable clinical outcomes related to immune activity and to guide selection among neoadjuvant chemotherapy or HER2-targeted therapy or immunotherapy.
引用
- Lee HJ, Lee JE, Jeong WG, et al. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes. AJR Am J Roentgenol. 2021. PMID: 34431365. doi:10.2214/AJR.21.26400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。